HCPLive

Rheumatoid Arthritis 
The MD Magazine Rheumatoid Arthritis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Sjögren's Syndrome Foundation Releases First Rheumatology Guide for Disorder
Saying the Guidelines fill a “significant clinical void,” the organization celebrated awareness of the rheumatic condition with a series of stringently approved recommendations for its treatment.
Philip J. Mease, MD, and John D. Reveille, MD, discuss the safety and efficacy of considering a new treatment for spondyloarthritis, specifically the use of IL-17 inhibition and methotrexate.
The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).
John D. Reveille, MD, and Philip J. Mease, MD, highlight the newer mechanisms of action in ankylosing spondylitis and psoriatic arthritis.
John D. Reveille, MD, and Philip J. Mease, MD, outline the inflammatory pathways in ankylosing spondylitis and psoriatic arthritis, as well as mention the newer mechanism of action.
You may have seen reports on the “treatment” on TV or heard that some of Beverley Hills’ richest citizens are raving about it, but whole body cryotherapy (WBC) doesn’t yet have the data to back up the many health benefits claimed by its boosters.
Philip J. Mease, MD, and John D. Reveille, MD, discuss the strategies for TNF-inhibitor cycling in spondyloarthritis.
Analysis of a Danish registry found that a switch from infliximab (Remicade) to a biosimilar called Remsima did not appear to change disease activity status or increase the risk of flares in patients with psoriatic arthritis or rheumatoid arthritis.
The Fibromyalgia Rapid Screening Tool (FiRST) can help physicians make the determination, but just how reliable is it?

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$